An immunotherapy helps patients live years longer without their cancer getting worse or coming back, a major phase III trial has found. Pembrolizumab kept cancer at bay for some patients for an ...

Jacqueline joined The Generations Study research team in 2022. Prior to joining the study, she has 14 years of experience working in the NHS in acute hospital, education, and primary care settings, ...

Lucy Dan earned her Master's degree in biological sciences from Durham University. She is a ICR/Imperial Convergence Science Centre student and will investigate novel ways to target the activities of ...

Amy McGeoch earned her Bachelor's degree in biochemistry from the University of Leeds. She plans to investigate the involvement of cyclin-dependent kinase complexes in non-canonical pathways such as ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned. According to a new modelling study, published in the journal ...

The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Results released at the ...

Image of human melanoma tissue, with melanoma cells in green and purple extracellular matrix fibres arranged perpendicular at the border of the tumour. Credit Oscar Maiques Carlos Scientists have ...

Scientists at The Institute of Cancer Research, London, have found a way to identify people with inflammatory bowel disease (IBD) who are at the highest risk of developing bowel cancer. IBD includes ...

In the largest and most comprehensive study of its kind, researchers have provided further evidence that a hormone responsible for regulating breast development acts as a risk factor for breast cancer ...

The Institute of Cancer Research has welcomed new plans to deliver around one million square feet of state-of-the-art research and laboratory space for life-sciences companies in Sutton, south London, ...